🚨 BIG NEWS in Cell Therapy! 🚨
New donor selection guidelines—developed with @CIBMTR & partners—are now published in the Journal for Transplantation and Cellular Therapy! 🧬
They reflect the latest in GVHD, expanded donor options & search strategies.
🔗 https://t.co/xNqO8HOrG0
Updated allogeneic stem cell donor guidelines from the CIBMTR/NMDP. A collaborative effort with many wonderful colleagues. Guidelines are adapted for donor selection when using PTCY.
https://t.co/UqXxine4Sl
Proud to share @JCO_ASCO paper of the ACCESS study run by @CIBMTR and sponsored by @nmdp_org 145 recipients of MMUD grafts using PTCy experienced outcomes similar to matched transplants, including <7/8 grafts. 59% of patients were diverse!
NEW study results just published in @JCO_ASCO: Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis Following Mismatched Unrelated Donor PBSC Transplantation. Read more: https://t.co/i1Vk9zQoAk
For heme/onc fellows that are interested in specialized training in cellular therapy, @MSKCancerCenter offers an advanced fellowship in BMT/Cellular Therapy!
DM me with specific questions, details 👇👇👇I’ll be at #ASH24 if you want to meet.
https://t.co/wL2dNoC3fs
New CIBMTR Research – the first analysis from @BMTCTN 1702! Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional Trial. Read more, here:
https://t.co/9c1QatT47W
Very pleased to share our collaborative work with @MayoClinic@MSKCancerCenter. We used AI to evaluate pre transplant ECG images to predict arrhythmia after #BMT. AI-ECG predicted death after allogeneic HCT.
https://t.co/uQFfG2sNWA
We believe the use of computer vision on ECGs to predict cancer treatment toxicity is a new paradigm in personalized cancer care, and that this approach may be applicable to other cancer treatments that may be cardiotoxic. More to come!
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors ➡️ https://t.co/z6TgWikO34 @BrianShafferMD@DrStevenDevine#hemonc